Cure Today: First-Line Enhertu Combo Gets Priority Review in HER2+ Metastatic Breast Cancer
Enhertu plus Perjeta received FDA priority review for first-line treatment of HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.
Monthly Prescribing Reference: Enhertu Plus Pertuzumab Approved for First-Line HER2+ Breast Cancer
WebMD: Enhertu Plus Pertuzumab: New First-Line Option for Advanced HER2-Positive Metastatic Breast Cancer
Enhertu Plus Pertuzumab: New First-Line Option for Advanced HER2-Positive Metastatic Breast Cancer
MedCity News: AstraZeneca, Daiichi Sankyo ADC Enhertu Moves Up to First-Line Use in Breast Cancer
Enhertu, a targeted cancer therapy from partners AstraZeneca and Daiichi Sankyo, may now be used as a first-line treatment for advanced cases of breast cancer, making it the first new approved ...
AstraZeneca, Daiichi Sankyo ADC Enhertu Moves Up to First-Line Use in Breast Cancer
Labroots: Drug Regimen Shows Efficacy as a First-Line Treatment for HER2+ Breast Cancer
Drug Regimen Shows Efficacy as a First-Line Treatment for HER2+ Breast Cancer
Monthly Prescribing Reference: Trastuzumab Deruxtecan + Pertuzumab Under Review For First-Line HER2+ Metastatic Breast Cancer
Trastuzumab Deruxtecan + Pertuzumab Under Review For First-Line HER2+ Metastatic Breast Cancer
Business Wire: TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
Morningstar: Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer